Yao Du

Yao Du

Auto-generated profile, based on publicly available information

Yao Du

Actxa Pte Ltd, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2020 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
Renzhe BiRenzhe Bi
Renzhe Bi
YDYao Du
Yao Du
GSGurpreet Singh
Gurpreet Singh
JHJun-Hui Ho
Jun-Hui Ho
SZShuyan Zhang
Shuyan Zhang
MOMalini Olivo
Malini Olivo
Blood flow is an important indicator of human health status. Compromised blood flow may cause diseases, such as stroke,1 foot ulcer,2 and myocardial ischemia.3 Several optical technologies have been developed for blood flow measurement. Laser speckle contrast imaging (LSCI) methods4,5 have been developed for wide-field blood flow imaging of superficial tissue (∼1  mm).5 It is a powerful tool for visualization of blood vessels. However, the penetration depth limits its applications in deep tissue blood flow measurement. Since biological tissue is a highly scattering medium for light, several diffuse optical methods have been developed for blood flow measurement in deep tissue (up to ∼15  mm).6 Diffuse correlation spectroscopy (DCS)6 – 9 is one of the first noninvasive optical methods; it has been used to monitor deep tissue blood flow in human muscle,10 brain,11 and breast cancer.12 DCS has many advantages including noninvasiveness, portability, and high temporal resolution (up to ∼100  Hz).6 However, there are challenges for DCS systems. To acquire the intensity temporal autocorrelation function G2(τ), a single-mode (SM) fiber and a high-sensitivity single-photon counting avalanche photodiode (SPC-APD) have to be used for photon detection. To extend DCS into multiple channels, each detection channel requires one SPC-APD, which increases the hardware cost significantly. Diffuse speckle contrast analysis (DSCA) was developed as a cost-effective method for deep tissue blood flow measurement.13 – 16 DSCA uses the relationship between the speckle contrast of the diffused laser light and the blood flow index (BFI) in DCS to achieve a level of deep tissue blood flow measurements similar to that of DCS.13,17,18 The fiber-based DSCA system can be extended into multiple channels without significant additional cost.17 Several other deep tissue blood flow measurement modalities based on diffused laser speckle detection have been developed. Speckle contrast optical tomography19,20 achieves three-dimensional imaging of deep tissue blood flow. Diffuse speckle contrast flowmeter21 achieves a wearable sensor for cerebral blood flow monitoring in small animals.

21 February 2024 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
Renzhe BiRenzhe Bi
Renzhe Bi
Ruochong ZhangRuochong Zhang
Ruochong Zhang
LMLingyan Meng
Lingyan Meng
YDYao Du
Yao Du
JLJulie Low
Julie Low
MOMalini Olivo
Malini Olivo
We present a robust, cost-effective (<2000 USD), and portable optical diffuse speckle pulsatile flowmetry (DSPF) device with a flexible handheld probe for deep tissue blood flow measurement in the human foot as well as a first-in-man observational clinical study using the proposed optical device for tissue ischemia assessment and peripheral artery disease (PAD) diagnosis. Blood flow in tissue is inherently pulsatile in nature. However, most conventional methods cannot measure deep tissue-level pulsatile blood flow noninvasively. The proposed optical device can measure tissue-level pulsatile blood flow ∼6 mm underneath the skin surface. A new quantitative tissue perfusion index (TPIDSPF) based on frequency domain analysis of the pulsatile blood flow waveform is defined to assess tissue ischemia status. Through a clinical study involving 66 subjects, including healthy individuals and diabetes patients with and without PAD, TPIDSPF demonstrated strong correlations of 0.720 with transcutaneous tissue partial oxygen pressure (TcPO2) and 0.652 with toe–brachial index (TBI). Moreover, among the three methods, TPIDSPF demonstrated the highest area under the curve for PAD diagnosis among diabetes patients, with a notable value of 0.941. The promising clinical results suggest that the proposed optical method has the potential to be an effective clinical tool for identifying PAD among the diabetic cohort.

8 January 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
ESEka Widrian Suradji
Eka Widrian Suradji
SDSatvinder Dhaliwal
Satvinder Dhaliwal
ZLZhang Li-Feng
Zhang Li-Feng
EZEntong Zhou
Entong Zhou
ALAmos Lim
Amos Lim
SASeng Bin Ang
Seng Bin Ang
Background: Diabetes mellitus (DM) is a major noncommunicable disease with a significant increase in prevalence, especially in low- and middle-income countries. The latest International Diabetes Federation Diabetes Atlas (2025) reports that 11.1% of the adult population (20 to 79 years old) is living with diabetes, with over 4 in 10 unaware of their condition. Early diagnosis and treatment of diabetes reduce the risk and slow the progression of debilitating complications, such as amputation, vision loss, renal failure, cardiovascular disease, dementia, some cancers, and infections like tuberculosis and severe COVID-19. Current screening methods for diabetes are invasive and costly. This has limited their utilization, especially in high-density populations and low- and middle-income countries such as Indonesia. Blood Glucose Evaluation and Monitoring (BGEM) is a machine learning algorithm developed by Actxa to analyze photoplethysmography data from wearable devices for diabetic risk assessment. Its noninvasive and user-friendly nature makes it a strong candidate for fulfilling the need for a diabetes screening or monitoring tool. Objective: The aim of this study is to collect a large and more diverse dataset for the training of BGEM machine learning models. This dataset is intended to improve the model’s generalizability and to evaluate its performance across different age groups, racial groups, and skin types, with the goal of enhancing accuracy and robustness for diabetes risk assessment and glucose monitoring. Methods: Adult participants aged 18 years and above, with either a diabetic or a nondiabetic history, who reside in Greater Jakarta Area, Indonesia, were approached for recruitment. Blood glucose was assessed using laboratory blood analysis from capillary or plasma samples after fasting and at 1, 2, and 3 hours after a meal. BGEM data were also collected at each of these time points. Anthropological measurements with a standardized questionnaire on physical activity, demographic information, respondent’s diabetic status, and current medications taken were also collected. Results: Between June and October 2024, 885 participants were enrolled. Eight photoplethysmography recordings per participant were collected across 4 meal time points using 2 wearable devices in addition to the collection of clinical measurements, blood sampling, and related questionnaires. Conclusions: This protocol paper outlines the methodology designed for assessing and interpreting participants’ blood sugar profiles, especially on demographic variability, in order to evaluate BGEM, a photoplethysmography-based artificial intelligence model designed to estimate blood glucose levels and diabetic risk. The clinical trial was conducted on Indonesian participants with and without diabetes while considering various influencing factors. This dataset is designed to enable assessment of the model’s performance across diverse racial, risk factors, and skin-type groups, with the aim of making the model more valid and reliable.